New Triple-Drug attack aims to shrink untreatable liver tumors
NCT ID NCT06698250
First seen Nov 06, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study tests whether adding a targeted drug (zanzalintinib) to two immunotherapy drugs (durvalumab and tremelimumab) can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. About 40 adults who have not had prior systemic therapy will participate. The goal is to find the best dose and measure how many patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neal Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mays Cancer Center, UT Health San Antonio
NOT_YET_RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.